Literature DB >> 12358845

Comparison of different techniques for detection of anti-HLA antibodies in sera from patients awaiting kidney transplantation.

M Uboldi de Capei1, L Praticò, E S Curtoni.   

Abstract

The aim of the present study was to compare different techniques of HLA antibody detection in patients waiting for a transplant. Two methods of HLA antibody screening were compared: the complement-dependent cytotoxicity (CDC) test and the enzyme-linked immunosorbent solubility assay (ELISA). Three different commercial kits for the latter assay were tested: the kits were produced by One Lambda (O.L.) and SANG STAT for prescreening and specificity determination, and GTI only for prescreening. Of the two techniques, only CDC can detect IgM. The study included 207 serum samples selected from 192 patients waiting for a first kidney transplant. The conclusions are that O.L. is more sensitive than CDC and the other ELISA kits and is much faster for analysing a serum (taking only a few hours), but costs about 16 times more than CDC and does not detect IgM antibodies, so can be used only in support of CDC.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12358845     DOI： 10.1046/j.1365-2370.2002.00334.x

Source DB:  PubMed          Journal:  Eur J Immunogenet        ISSN： 0960-7420


  7 in total

Review 1.  Sensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes.

Authors:  Gerald Schlaf; Beatrix Pollok-Kopp; Wolfgang W Altermann
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

2.  Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response.

Authors:  Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Garth H Utter; Cathy Schechterly; Mila Lebedeva; Eva Operskalski; Naomi L Luban; Harvey Alter; Michael P Busch; Sherrill J Slichter; Philip J Norris
Journal:  Transfusion       Date:  2013-06-30       Impact factor: 3.157

3.  Agreement among HLA antibody detection assays is higher in ever-pregnant donors and improved using a consensus cutoff.

Authors:  Danielle M Carrick; Bryce Johnson; Steven H Kleinman; Robert Vorhaben; Suzette C Chance; Jar-How Lee; John D Roback; Suchitra Pandey; Yu Sun; Michael P Busch; Philip J Norris
Journal:  Transfusion       Date:  2010-11-18       Impact factor: 3.157

4.  Complement-dependent cytotoxicity (CDC) to detect Anti-HLA antibodies: old but gold.

Authors:  Patrícia Keiko Saito; Roger Haruki Yamakawa; Lucieni Christina Marques da Silva Pereira; Waldir Veríssimo da Silva; Sueli Donizete Borelli
Journal:  J Clin Lab Anal       Date:  2014-02-27       Impact factor: 2.352

5.  Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.

Authors:  Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Mila Lebedeva; John W Heitman; Michael P Busch; Sherrill J Slichter; Philip J Norris
Journal:  Blood       Date:  2013-02-07       Impact factor: 22.113

6.  C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.

Authors:  Rachael P Jackman; Jar-How Lee; Rui Pei; Douglas Bolgiano; Mila Lebedeva; Sherrill J Slichter; Philip J Norris
Journal:  Transfusion       Date:  2016-04-15       Impact factor: 3.157

7.  Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching.

Authors:  Gerald Schlaf; Beatrix Pollok-Kopp; Till Manzke; Oliver Schurat; Wolfgang Altermann
Journal:  NDT Plus       Date:  2010-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.